Q2 2026 saw 23% revenue growth and 44% adjusted EBITDA growth, driven by strong performance in both Pharmacy Solutions and Provider Services. Guidance for 2026 was raised, with robust cash flow, reduced leverage, and continued investment in technology and M&A.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.